🔎 Trials Near Me

Utama › Kanser Payudara › Indiana › Indianapolis

Kajian klinikal Kanser Payudara di Indianapolis, IN

20 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Indianapolis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Mengambil pesertaFasa 3
  • Investigative Clinical R of Indiana, Indianapolis
Umur 18 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05827081

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06625775

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
Umur 18 hingga 45 · Wanita · Dikemas kini 1 Okt 2026 · NCT05557877

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Mengambil pesertaFasa 1/2
  • Community Health Network, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06324357

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Mengambil pesertaFasa 3
  • Franciscan Health ( Site 0077), Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Mengambil peserta
  • Indiana University, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Mengambil pesertaFasa 3
  • Indiana University Health University Hospital, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Mengambil pesertaFasa 2
  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Umur 18 ke atas · Wanita · Dikemas kini 22 Sep 2026 · NCT07287098

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Mengambil pesertaFasa 1
  • Indiana University (IU) School of Medicine, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213791

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Mengambil pesertaFasa 3
  • Community Health Network, Inc, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06982521

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Mengambil pesertaFasa 2
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
  • Sidney and Lois Eskenazi Hospital, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT05846789

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Mengambil pesertaFasa 3
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • Sidney and Lois Eskenazi Hospital, Indianapolis
  • Community Cancer Center East, Indianapolis
  • dan 5 lagi
Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926

HER2 Vaccine for Locally Advanced Breast Cancer

Mengambil pesertaFasa 1
  • Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06949410

Exercise in Metastatic Breast Cancer: EMBody

Mengambil peserta
  • Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Apr 2026 · NCT05468034

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Mengambil pesertaFasa 3
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • Franciscan Health Indianapolis, Indianapolis
  • Franciscan Health Mooresville, Mooresville · 16 mi jauh
Umur 50 hingga 70 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT04852887

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Mengambil pesertaFasa 2
  • Indiana University, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Apr 2026 · NCT04841148

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Mengambil pesertaFasa 1/2
  • Research Site, Indianapolis
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06956690

NearWave Optical Molecular Monitoring

Mengambil peserta
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
Umur 18 ke atas · Wanita · Dikemas kini 17 Feb 2026 · NCT06744465

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Mengambil pesertaFasa 3
  • Franciscan Health Indianapolis, Indianapolis
  • Franciscan Health Mooresville, Mooresville · 16 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Okt 2025 · NCT03418961

Kajian Kanser Payudara di bandar lain

Kajian lain di Indianapolis

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.